Insulet (Nasdaq:PODD) shared new clinical evidence for its first fully closed-loop automated insulin delivery system for type 2 diabetes.

Insulet to Present EVOLUTION 2 Results on Omnipod® Fully Closed-Loop System for Adults with Type 2 Diabetes at ATTD ...

Outcomes from EVOLUTION 2 study include 68% time in range with no boluses Diverse multicenter feasibility study highlights the promise of future Omnipod innovation to address unmet needs, improve ...

The dream of a completely closed-loop system for diabetes management is now closer than ever for many Type 1 diabetes patients, thanks to the widespread U.S. launch of a completely automated, ...

Insulet Stock: why GLP-1 fears are overblown, with growth driven by Europe/MENA expansion. Read here for a detailed analysis on PODD stock.

As Americans flock to nearby orchards for festive bouts of autumn apple picking, Insulet is celebrating a particularly bountiful stateside Apple harvest itself. The diabetes devicemaker has earned FDA ...

Insulet has received reports that heat generated by a poor connection between the Omnipod 5 cable and port has caused them to melt, deform, or discolor. Insulet reported a medical device corrections ...

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced ...

Early clinical trials established the safety and feasibility of closed-loop insulin delivery, but the 2019 iDCL trial1 marked the first large, outpatient, randomised, controlled trial to show a ...

Fully Closed-Loop System Feasibility Study to be presented at Insulet Symposium and in e-Poster during ATTD 2026 Real World Evidence of Settings Optimization in Omnipod 5 Users will also be shared ...